NeuroSense Therapeutics Ltd

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

View video here: Link CAMBRIDGE, Mass. , July 6, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense CEO Provides Q2 2023 Update

CAMBRIDGE, Mass. , June 1, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023

96% of participants who completed the trial opted to receive treatment with PrimeC in a 12-month open label extension Topline results expected Q4 2023 CAMBRIDGE, Mass. , May 15, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial

Statistically significant decreased levels of novel biomarker AGO2 (p= 0.002) observed in newly diagnosed people living with Parkinson's disease (PD) compared to healthy individuals NeuroSense's combination platform has been observed in a clinical trial to induce an increase of AGO2 in ALS patients, indicating therapeutic potential in PD NeuroSense is exploring co-development of PD asset with potential collaborators CAMBRIDGE, Mass. , May 2, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson's Biomarker Study

CAMBRIDGE, Mass., April 17, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the Company's clinical and operational developments during the first quarter of 2023.

NeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment

In vitro studies to test the effects of PrimeC on key pathways involved in ALS including TDP-43 accumulation, autophagy defects, mitochondrial dysfunction, and oxidative stress Preliminary results from this collaboration will be presented by Dr. Zimri at the upcoming AD/PD 2023 Advances in Science & Therapy Conference PrimeC is currently being evaluated in PARADIGM, a Phase 2b ALS trial CAMBRIDGE, Mass. , March 27, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS

Biomarkers show potential efficacy PrimeC is currently being evaluated for the treatment of ALS in a Phase 2b study with topline results expected in H2 2023 Phase 2 double-blind proof-of-concept AD study is expected to commence in H1 2023 CAMBRIDGE, Mass. , March 23, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference

CAMBRIDGE, Mass., March 22, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced today that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2022, as filed with the Securities and Exchange Commission, is available through its website (https://www.neurosense-tx.com), and provided a business update.

NeuroSense Announces Year End 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass. , March 16, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics to Participate in BIO-Europe Spring

CAMBRIDGE, Mass. , March 14, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NEUROSENSE THERAPEUTICS LTD. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON, TUESDAY, MARCH 21 AND TUESDAY, MARCH 28, 2023

View video here: LINK CAMBRIDGE, Mass. , Feb. 13, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense CEO Recaps 2022 Achievements & Presents 2023 Catalysts

QuantalX's direct electrophysiology imaging technology (Delphi-MD) expected to provide multiple clinically objective and accurate measurements in NeuroSense's Phase 2 double-blind proof-of-concept clinical study in Alzheimer's disease, expected to commence in H1 2023 CAMBRIDGE, Mass. and KFAR SABA, Israel , Feb. 9, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases

Creative Medical Technology Holdings

Geovax Labs

Quantum Computing

Zhongchao

Stock Market News Has These Penny Stocks On Traders' Watch Lists This Week. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 5 To Watch After News This Week

PARADIGM protocol is  approved in four countries: Israel, Italy, Canada, and Germany Topline results expected in H2 2023 CAMBRIDGE, Mass. , Feb. 8, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial

Receives regulatory approval from Health Canada to commence enrollment PARADIGM topline read-out expected H2 2023 CAMBRIDGE, Mass. , Feb. 6, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study

Cuentas

Genius Group Ltd

Use these tips for making money with penny stocks right now The post 3 Ways to Make Money With Penny Stocks Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Ways to Make Money With Penny Stocks Right Now

NeuroSense (NASDAQ: NRSN ) stock is taking off on Thursday as investors react to data from a biomarker study concerning Alzheimer's disease ( AD ). The clinical trial covers the use of NeuroSense's combination platform therapy for the treatment of AD.

Why Is NeuroSense (NRSN) Stock Up 98% Today?

Elevated levels of novel biomarker TDP-43 in Alzheimer's disease (AD) show the therapeutic potential of NeuroSense's combination platform Phase 2 double-blind proof-of-concept clinical study expected to commence in H1 2023 CAMBRIDGE, Mass. , Jan. 19, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study

CAMBRIDGE, Mass. , Dec. 1, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass. , Nov. 16, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS

NeuroSense Therapeutics receives FDA clearance to commence patient enrollment in the U.S. with PrimeC, a novel combination therapy Follows a successful U.S. pharmacokinetic (PK) study which confirmed PrimeC's favorable extended release properties CAMBRIDGE, Mass. , Nov. 15, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study

CAMBRIDGE, Mass. , Oct. 27, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences

CAMBRIDGE, Mass , Oct. 21, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in the BIO-Europe® Partnering Conference on October 24-26, 2022 in Lepzing, Germany.

NeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, Germany

Amylyx Pharmaceuticals

View the Nasdaq Opening Bell Ringing & CEO Message Here: LINK CAMBRIDGE, Mass. , Oct. 18, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video

Investors and analysts interested in participating in the Summit via webinar may register here: LINK   CAMBRIDGE, Mass. , Oct. 12, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

News for NeuroSense Therapeutics Ltd Stock (NRSN)